Monday, 30 April 2007 “The sanctioning of countries for using legitimate and important flexibilities in the TRIPS agreement brings shame to all U.S. citizens who are increasingly seen in Thailand and elsewhere as bullies and hypocrites.” The following is the… Continue Reading
On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading
Knowledge Ecology International: Q&A Session on Thai White Paper (Facts and Evidences on the 10 Burning Issues Related to the Government Use of Patents on Three Patented Essential Drugs in Thailand) Geneva, Switzerland 8 March 2007 Thiru Balasubramaniam On Thursday,… Continue Reading
March 2, 2007 Secretary of the Expert Committee on the Selection and Use of Essential Medicines (2007)Department of Medicines Policy and Standards (PSM)Health Technology & PharmaceuticalsWorld Health OrganizationCH-1211 Geneva 27Switzerland Via e-mail: emisecretariat@who.int RE: Request for changes in the WHO Model… Continue Reading
12 February 2007
Knowledge Ecology International (KEI) is a non-governmental organization that searches for better outcomes, including new solutions, to the management of knowledge resources.
The following is the text of a letter to Dr. Margaret Chan, Director-General Elect, World Health Organization (WHO), asking for a review of the Essential Drugs List (EDL) as it relates to patented products. Consumer Project on Technology http://www.cptech.org December… Continue Reading
March 2006
CPTech Response to 2006 PhRMA “Special 301” Submission for Chile
The “Special 301” Report is a report that the office of the U.S. Trade Representative (USTR) submits annually to the House Ways and Means Committee and the Senate Finance Committee on the adequacy and effectiveness of intellectual property rights protection around the world. The report identifies those countries that the USTR consider “deny adequate and effective protection for IPR or deny fair and equitable market access for U.S. persons that rely on intellectual property protection”.
This is a joint statement by that NGOs presented to negotiators in 2005, as the WTO considered an amendment on TRIPS and public health, to address cases where medicines would be exported to countries with “insufficient or no manufacturing capacity.”… Continue Reading
Original page: http://www.cptech.org/ip/health/tamiflu/christinelagarde.html Christine LAGARDE asked to change EU “opt-out” of 30 August 2003 decision regarding imports of generic medicines manufactured under a compulsory license To: Christine LAGARDE, Ministre déléguée au Commerce extérieur, France From: Manon Ress and James Love,… Continue Reading
Original page: http://www.cptech.org/ip/health/tamiflu/cptech-mandelson10192005.html CPTech Letter to EC Director General of Trade Peter Mandelson 19th October 2005 Commissioner Mandelson EUROPEAN COMMISSION DG Trade 200 rue de la Loi B-1049 BRUSSELS Dear Commissioner Mandelson TRIPS Agreement and Avian Influenza We ask the… Continue Reading